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Summary
The bacterial toxin pyolysin (PLO) belongs to the family of Cholesterol-Dependent Cytolysins 
(CDCs), which form large, oligomeric pores in cholesterol-containing membranes. Monomeric 
CDC molecules have a structure of four domains, with domains 2 and 3 packed against each 
other. After binding to target membranes containing cholesterol, toxin monomers oligomerize 
into pre-pore complexes. Trans-membrane pores form when the pre-pores insert into the lipid 
bilayer.  Membrane  insertion  requires  each  subunit  in  the  pre-pore  to  undergo  a  significant 
change  in  conformation,  including  the  separation  of  domains  2  and  3.  We  here  describe  a 
pyolysin mutant with an engineered disulfide bond between domains 2 and 3 that is unable to 
complete  this  conformational  change and thus  does  not  form pores.  In  contrast  to  a  similar 
mutant previously described for the homologous toxin perfringolysin O, the disulfide-tethered 
mutant does not form pre-pore oligomers, indicating that it is already inhibited at the stage of 
oligomerization. When mixed with wild type PLO, the mutant partially inhibits oligomerization 
of the latter, so that the resulting hybrid oligomers are reduced in size and arc-shaped rather than 
ring-shaped. Osmotic protection experiments indicate that such oligomers can form functional 
pores of reduced size. These findings indicate that conformational flexibility between domains 2 
and  3  is  required  for  oligomerization.  Moreover,  membrane  insertion  can  be  triggered  in 
oligomers  that  contain  some  insertion-deficient  subunits  and  is  therefore  only  partially 
cooperative.
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Introduction
Arcanobacterium pyogenes is  a  Gram-positive  bacterial  pathogen of  livestock.  An important 
virulence factor of A. pyogenes is the cytolytic toxin pyolysin (PLO). This toxin is a member of 
the large group of toxins known as the Cholesterol Dependent Cytolysins (CDC), which take 
their name from their absolute dependence on cholesterol in the target membrane for activity. 
These toxins form exceptionally large oligomeric trans-membrane pores (1), which consist of 40-
50 monomers and have diameters of up to 30 nm (2).
Crystallographic studies on other members of the CDC family, namely perfringolysin O (PFO) 
and intermedilysin (ILY) show that the monomeric toxin molecule is elongated and contains four 
domains rich in β-sheet structure (3; 4). Upon binding to a target membrane, molecules diffuse 
laterally on the surface, interact with other bound CDC monomers, and form a pre-pore complex 
(5). Subsequently, a profound conformational change occurs that results in the formation of the 
trans-membrane pore (6). During this change, domain 2 dissociates from domain 3, whereupon 
two initially α-helical segments in domain three change shape into β-hairpins and become deeply 
inserted into the membrane (7).
In  a  previous  study  on  the  homologous  toxin  perfringolysin  O,  it  had  been  reported  that 
introduction of a disulfide bond between domains 2 and 3 prevented membrane insertion, while 
still  allowing  the  assembly  of  pre-pore  oligomers  (8).  This  observation  suggests  that 
conformational flexibility of domain 2 relative to domain 3 is not required up to the pre-pore 
stage. We here report that a homologous disulfide mutant derived from the homologous toxin 
pyolysin fails to oligomerize. The mutant also interferes with the activity of wild type PLO in a 
dose-dependent manner. At large molar excess over the latter, inhibition of hemolysis is virtually 
complete,  whereas at equimolar ratio hemolysis  is partially preserved, but both oligomer and 
pore size is reduced. These findings indicate that conformational flexibility between domains 2 
and 3 is required for proper oligomerization. Furthermore, they show that membrane insertion of 
oligomers is cooperative, yet completion of oligomerization to ring shape is not necessary.
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Materials and Methods
Construction,  Expression  and  Purification  of  PLO  Mutants.  The  mutants  created  for  this 
investigation were based on on the plasmid pJGS59 (9) encoding the PLO wild type gene, fused 
to  an  N-terminal  hexa-histidine  purification  tag.  Site  directed  mutagenesis  was  performed 
according  to  (10).  Introduction  of  mutations,  and  absence  of  any  unintended  second  site 
mutations was confirmed by DNA sequencing (McMaster University, ON). For expression, the 
mutant plasmids were transformed into E. coli BL21 and cultured in 2xYT broth supplemented 
with 0.5mM IPTG (BioShop, Burlington ON) for protein expression. After harvesting, cells were 
lysed using a Emulsiflex C5 Emulsifier (Avestin, Ottawa ON) and the protein was purified using 
a BioRad Biologic LP liquid chromatography system (Mississauga ON) with a nickel agarose 
column (Qiagen, Mississauga ON). 
Chemical Modification of Cysteine Residues. Protein samples were transferred to labelling buffer 
consisting of 50mM Tris, 150 mM NaCl, 1mM EDTA (BioShop, Burlington ON) pH 7.5 using 
gel filtration. The single cysteine mutants were supplemented to 1 mM of either Fluorescein-5-
Maleimide  (Biotium  Inc,  Hayward  CA),   Rhodamine  Red  Maleimide  or  N,N’-dimethyl-N-
(iodoacetyl)-N’-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine  (IANBD;  both  from 
Invitrogen, Burlington ON). The samples were incubated at 25ºC for 60 minutes and excess label 
was  removed  using  gel  filtration  chromatography.  Labelling  efficiencies  of  85-90%  for 
fluorescein and 70-80% for rhodamine an IANBD were obtained,  as determined by UV-Vis 
absorbance and extinction  coefficients  of 83,000 M-1cm-1 for  fluorescein,  91,000 M-1cm-1 for 
rhodamine and 24 667 M-1cm-1 for IANBD. 
Preparation of Red Blood Cells and Ghost Membranes. For hemolysis assays, aliquots of 400 μl 
sheep red blood (Cedarlane, Burlington, ON) cells were diluted to 1 ml with PBS buffer (16mM 
K2HPO4, 150mM NaCl, 1mM EDTA, pH 7.5), centrifuged in a tabletop centrifuge for 4 minutes, 
and the supernatant removed to yield a 100 μl RBC pellet.  The pellet was washed with PBS 
buffer by centrifugation until the supernatant remained clear. The pellet was resuspended again 
to a final volume of 1 ml to a concentration of 10%. From this, 1% RBC working solutions were 
made. To prepare ghost membranes, 400 μl sheep RBC were mixed with 600 μl cell lysis buffer 
(5 mM NaCl,  5  mM Na2HPO4 pH 7.0)  and centrifuged  at  13,000 rpm for  10 minutes.  The 
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supernatant was removed and the pellet washed until both the supernatant became clear and the 
pellet translucent. The pellet was made up to 1 ml with PBS buffer.
Hemolysis  Assay.  Two-fold  serial  dilutions  were  made  of  PLO-DS (initial  concentration  30 
μg/ml) in a 96-well plate with PBS buffer, in the presence and absence on 5 mM dithiothreitol 
(DTT;  BioShop,  Burlington ON).  Sheep red  blood cells  were added to each well  to  a  final 
concentration of 0.5% and incubated at  37  ºC for 30 minutes.  The decrease in cell  turbidity 
corresponding to hemolysis was monitored at a wavelength (650 nm) outside the absorbance of 
hemoglobin, using a SpectroMax Plus 384 Microplate Spectrophotometer (Molecular Devices, 
Sunnyvale CA). Wild type PLO (30ug/ml) was admixed with PLO-DS to ratios of 1:1, 1:2, 1:4, 
1:8 and 1:12 and tested for hemolytic activity as above.
Fluorescence  Spectroscopy.  All  samples  containing  labelled  protein  were  made  to  a  final 
concentration of 1 μM, with 1% (v/v) of red cell ghost membranes. For all fluorescence assays,  
fluorescein- and rhodamine- labeled toxin was combined in a 1:1 ratio (0.5  μM each). Steady 
state  fluorescence spectra  were recorded on a PTI QuantaMaster spectrofluorimeter  using an 
excitation wavelength of 465 nm with emission scans recorded from 495 to 620 nm, using 2 mm 
excitation  and  emission  slit  widths.  The  labeled  toxin  samples  were  incubated  with  ghost 
membranes  to  a  final  membrane  concentration  of  1% (v/v)  and  incubated  at  37  ºC  for  30 
minutes.   The  membranes  were  then  collected  by centrifugation  and resuspended  in  buffer. 
Spectra were subtracted with erythrocyte ghost suspension as a blank. 
Time-resolved  fluorescence  was  measured  using  an  FT-100  compact  fluorescence  lifetime 
spectrometer  (PicoQuant,  Berlin,  Germany)  using  an  LDH-P-C-470 LED laser  light  source. 
Fluorescein  emission  was  isolated  using  a  520±5nm bandpass  filter  (Andover,  Salem,  NH). 
Decays were fitted using FluoFit software (PicoQuant) fitting to three lifetime components from 
which the average lifetime <τ> was calculated, using the formula
τ≥
Σαi τ i
Σα i
where αi represents the amplitude at time zero and τi is the lifetime of the  ith component. All 
lifetime decay values were fitted to χ2 values ≤ 1.2.
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Size  Exclusion  Chromatography.  In  order  to  determine  relative  sizes  of  hybrid  oligomer 
complexes formed, samples of labeled PLO-R219C-F were made to 1 μM concentration, with an 
equal amount of unlabeled PLO-DS. Ghost membranes were added to a final concentration of 
20% (v/v). Samples were incubated at 37  ºC for 30 minutes, centrifuged at 13,000 rpm for 10 
minutes, after which the supernatant was removed. Membranes were dissolved using 5% sodium 
deoxycholate,  and  the  samples  were  made  to  a  final  volume  of  1ml.  Size  exclusion 
chromatography was performed on a BioRad BioLogic FPLC (described in Protein Expression 
and  Purification  section)  using  a  Sephacryl  S-400  column  equilibrated  with  elution  buffer 
consisting of 20 mM Tris, 150mM NaCl, 1 mM EDTA and 0.25% (w/v) sodium deoxycholic 
acid  (BioShop,  Burlington  ON)  pH  8.5.  Eluted  fractions  were  collected  and  analyzed  for 
fluorescein fluorescence. 
Osmotic Protection Assay.  A standard buffer of 10 mM K2HPO4, 25mM NaCl at pH 7.5 was 
supplemented  with either  Dextran  6 to  13% (w/v)  or  Dextran  40 (both,  Fluka BioChemika,  
Switzerland) to 17% (w/v). Washed sheep erythrocytes were suspended in the above buffers to a 
final concentration of 0.5%. The suspension was dispensed into the wells of a microtitre plate 
and supplemented with 2.5 μg/ml of wild type PLO either alone, or supplemented with the same 
amount or twice the amount of PLO-DS.  The time course of hemolysis  was followed during 
incubation at 25 ºC for 30 minutes by measuring the OD at 650 nm in a SpectraMax Plus 384 
Microplate Spectrophotometer. 
Transmission Electron Microscopy.  Wild type PLO and of PLO-DS, alone or in mixtures as 
indicated in the Results section, were incubated at a total protein concentration of 0.125 mg/ml 
with  cholesterol  crystals  (0.5  mg/ml,   prepared  according  to  (11)) for  30  minutes  at  room 
temperature. The samples were subjected to negative staining with 2% uranyl acetate according 
to  (12).  TEM study of the negatively stained specimens was performed in a Phillips CM 100 
transmission electron microscope at 100 kV. Digital images were recorded using an Optronics 
1824x1824 pixel CCD camera with an AMT40 version 5.42 image capture engine, supplied by 
Deben (Bury St. Edmunds, UK).
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Results
Hemolytic  Activity  of  the  disulfide-tethered  mutant. The  hemolytic  activity  of  the  disulfide 
mutant R219C/G85C, or PLO-DS for short. The PLO-DS is shown in Figure 2. Wild type PLO 
(PLO-WT) exhibits 50% hemolysis at approximately 400 ng/ml. In contrast, PLO-DS shows no 
hemolytic activity up to a concentration of 30 μg/ml. However, when PLO-DS is reduced with 
DTT, the hemolytic activity was restored to a level similar to that of wild type pyolysin. This  
indicates that the functional impairment is due to the disulfide bond and not to the substitutions 
of residues R219C or G85C individually. These findings are entirely analogous to those reported 
previously for the homologous mutant of perfringolysin O (8).
PLO-DS does not form oligomers. The disulfide mutant of perfringolysin O was reported to form 
pre-pores on membranes, with the same circular shape and diameter that also characterizes the 
final, membrane-inserted perfringolysin pores. In contrast to these prior findings, PLO-DS did 
not form any distinct, regular ring-shaped oligomers on PC/cholesterol liposome membranes (not 
shown) or cholesterol crystals (Figure 3A). 
Similarly, on cholesterol microcrystals, which provide a minimal but viable model substrate for 
CDCs (11; 13), the mutant failed to form typical oligomers as illustrated in Figure 3B. Therefore, 
the mutant  is  deficient  not only in its  ability  to  undergo membrane insertion,  but  is  already 
unable to properly oligomerize. Oligomerization of the mutant was restored upon reduction with 
dithiothreitol, which is in agreement with the observed restoration of hemolytic activity.
The lacking oligomerization of PLO-DS is also apparent in fluorescence energy transfer (FRET) 
experiments.  In  these  experiments,  PLO-DS  was  modeled  with  the  triple  mutant  PLO 
R219C/G85C/K328C, which in addition to the disulfide bond contains another cysteine residue 
amenable to covalent labeling. In both labeled and unlabeled form, the triple mutant functionally 
behaves like PLO-DS, exhibiting hemolytic activity only upon disulfide reduction with DTT. 
Wild type toxin was modeled with the single cysteine mutant N90C, which retains hemolytic 
activity in both labeled and unlabeled form (data not shown). 
The  mutants  were  labeled  with  fluorescein  and  rhodamine,  respectively.  Fluorescein  and 
rhodamine form an efficient donor-acceptor pair for FRET, with an R0 distance of approximately 
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50 Å (14), which is well above the distance of two adjacent subunits in CDC oligomers (2; 15). 
Accordingly,  when mixtures of fluorescein-  and rhodamine-labeled N90C are incubated with 
membranes, the formation of hybrid oligomers results in a strong reduction of the fluorescein 
emission (Figure 4A). In contrast, no such reduction is apparent with the triple mutant, indicating 
absence of oligomerization (Figure 4B). 
Effect of PLO-DS on the Oligomerization of Wild Type PLO. When PLO-DS was added to wild 
type PLO at equal amounts or in slight excess, oligomers were observed, but these were mostly 
incomplete and arc-shaped, indicating that oligomerization was partially inhibited by the mutant 
(Figure 3C). With PLO-DS present in tenfold excess, oligomerization was virtually completely 
inhibited (Figure 3D). 
The formation of oligomers of reduced size in equimolar mixtures of PLO-WT and PLO-DS was 
confirmed  with  size  exclusion  chromatography.  In  these  experiments,  wild  type  PLO  was 
replaced with the hemolytically active fluorescein-labeled cysteine PLO mutant (R219C). This 
mutant was incubated, with or without added PLO-DS, with sheep red cell membranes to induce 
oligomerization. The membranes were then solubilized with deoxycholic acid before application 
to a Sephacryl S-400 column. Oligomers formed from an equimolar mixture of PLO-DS and the 
active toxin elute  between the monomeric  toxin and oligomers formed from the active toxin 
mutant alone (Figure 5). Since the fluorescence signal tracks the labeled active mutant only, the 
retarded elution indicates that the disulfide mutant indeed causes the active toxin to end up in 
oligomers of reduced size.
FRET experiments combining N90C-fluorescein and the rhodamine-labeled triple mutant show 
an efficiency of FRET (Figure 4C) that is intermediate between those of the active (Figure 4A) 
and inactive (Figure 4B) mutants alone, indicating that the two proteins become incorporated 
into hybrid oligomers, although the formation of these hybrids appears to be less efficient than 
the oligomerization of active toxin alone. When wild type PLO or the unlabeled disulfide mutant 
is added to a mixture of N90C-fluorescein and N90C-rhodamine, they reduce FRET between the 
two labeled species, indicating the intercalation of unlabeled molecules between the labeled ones 
in hybrid oligomers (Figure 4D). This effect is greater with wild type toxin than with PLO-DS. 
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Nevertheless,  the result  shows that PLO-DS in hybrid oligomers is not restricted to terminal 
positions, and therefore that its incorparation does not terminate the growth of a hybrid oligomer.
Membrane insertion of active subunits in hybrid oligomers. With the disulfide mutant of PLO, it 
was shown that the loss of hemolytic activity correlated with the lacking insertion of the two β-
hairpins in domain 3 into the membrane (8). From the observation of hybrid oligomers forming 
between active PLO and PLO-DS, the question arise to what extent the active protein in such 
hybrids might still undergo membrane insertion. The membrane insertion of the two β-hairpins in 
domain 3 can be detected by labeling mutant cysteine residues located within them with the 
environmentally  sensitive  fluorescent  dye  nitrobenzoxadiazole  (NBD),  whose  fluorescence 
emission undergoes a pronounced increase in intensity and excited state lifetime, and a blue shift 
upon transition from an aqueous to a non-polar environment  (7). The insertion of hybrids was 
studied using the NBD-labeled mutants K231C and A329C, whose cysteine residues are located 
the first and second hairpin, respectively. When either NBD-labeled mutant was mixed with a 
twofold  excess  of  the  unlabeled  PLO-DS,  the  NBD  fluorescence  emission  was  reduced 
significantly compared to samples that were prepared in the same manner but with unlabeled 
PLO-WT instead of PLO-DS (Figure 6). However, in both cases, the NBD fluorescence was still  
well above of that observed with the equivalent amount of toxin not incubated with membranes. 
The steady-state spectra are in line with time-resolved fluorescence measurements. For mutant 
K231C, the average excited state lifetime of NBD was was 4.0 ns when mixed with wild type 
toxin, 3.2 ns when mixed with disulfide mutant, and 1.7 ns in the absence of membranes. For 
A329C, the lifetimes were 6.2 ns, 2.9 ns, and 2.1 ns, respectively. These findings indicate that 
PLO-DS inhibits  but does not completely abrogate membrane insertion of wild type PLO in 
hybrid oligomers.
Hemolytic activity of wild type PLO and PLO-DS mixtures.  The above observation of partial 
membrane insertion of oligomers formed from mixtures of active PLO and PLO-DS suggests 
that such mixtures should retain some hemolytic activity. This is indeed observed. The hemolytic 
activity of a given amount of wild type PLO is slightly reduced in the presence of an equal 
amount of PLO-DS, and moderately so with a twofold excess of PLO-DS. In contrast,  when 
PLO-DS is present in fourfold, it very strongly inhibits hemolysis (Figure 7). 
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Reduction of average pore size by PLO-DS. When PLO-DS is combined with active PLO, it is 
likely that only a small fraction of all resulting oligomers will not contain any PLO-DS at all.  
This suggests that the remaining extent of membrane insertion and pore formation observed with 
such mixtures is at least in part associated with hybrid oligomers. Since these hybrid oligomers  
are reduced in size, the pores associated with them should be smaller than those formed by full-
size, ring-shaped oligomers formed by wild type PLO alone. 
Differences in functional pore size can be studied in hemolytic assays using osmotic protection. 
In this method, the extracellular medium is supplemented with inert macromolecular solutes such 
as  dextran  that  counteract  the  osmotic  activity  of  the  intracellular  hemoglobin.  When  pore 
formation occurs, hemolysis will result only if the pores are large enough to permit equilibration 
of the macromolecular solutes across the membrane, so that they no longer maintain the balance 
with hemoglobin. On the other hand, if the effective diameter of the protecting solutes exceeds 
that of the pores, the solutes will remain excluded from the cell and continue to protect it from 
osmotic lysis. Differential protection by macromolecular solutes varying in size can be used to 
characterize the pore size.
In the experiment shown in Figure 8A, wild type PLO was incubated with red cells without 
dextran 6 and dextran 40, respectively. The dextrans cause only a very slight delay in the time 
course of hemolysis. This is consistent with the fact that the hydrodynamic diameters of dextran 
6 (Mr 6000) and dextran 40 (Mr 6000), at  approximately 3 and 10 nm, respectively  (16), are 
smaller than the diameter of ring-shaped PLO oligomers (1) and therefore do not afford osmotic 
protection against the latter.
The picture changes, however, when the wild type PLO is supplemented with one (Figure 8B) or 
two (Figure 8C) equivalents of disulfide mutant. Here, the time course of hemolysis is markedly 
slowed by dextran 6, and even more so by the larger dextran 40. This divergence indicates that  
some  of  the  pores  are  no  longer  permeable  to  the  dextran  molecules,  or  else  that  they  are 
sufficiently reduced in size to significantly slow down the permeation of dextran. On the other 
hand, with both dextran 6 and dextran 40, hemolysis ultimately occurs, which means that at least 
some pores  are  still  large enough to allow permeation  of dextran.  The pores formed by the 
mixtures of PLO-WT and PLO-DS therefore are heterogeneous in size yet smaller than those 
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formed by wild type PLO alone. This supports the conclusion that oligomers that contain both 
wild  type  PLO and PLO-DS can insert  into  the  membrane  and form pores.  It  confirms  the  
previous  contention  that  incomplete,  arc-shaped oligomers  can indeed form functional  trans-
membrane pores (17).
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Discussion
The results of this study show a remarkable and surprising difference between the disulfide-
tethered PLO mutant and the homologous mutant previously described for perfringolysin O (8). 
Whereas the latter mutant retains the ability to assemble into complete, ring-shaped pre-pores on 
membranes, PLO-DS does no longer oligomerize on its own. This discrepancy may be related to 
a subtle yet  long-ranging conformational change  that is triggered by membrane binding and 
whose interception  by mutagenesis  interferes  with proper  oligomerization  (18;  19).  It  seems 
possible that the presence of the disulfide bond may interfere with this conformational shift to 
different extents in PLO and perfringolysin, preventing oligomerization in one case but not the 
other. 
The notion that  the difference  in  the functional  defect  between the two disulfide  mutants  is 
quantitative rather than qualitative is supported by the finding that PLO-DS retains the ability to 
form hybrid oligomers with wild type PLO. A possible explanation of this observation would be 
a 'hemiplegic' inactivation of the mutant, such that it can attach to a growing oligomer of wild 
type molecules using its remaining active oligomerization surface, which would then leave the 
inactive one exposed and so terminate the further growth of the oligomer. In this case, however, 
PLO-DS should be confined to one end of a hybrid oligomer and be able to intercalate between 
active subunits. This is not in line with the observation that unlabeled PLO-DS can significantly 
reduce FRET between labeled, hemolytically active mutants within hybrid oligomers.
Another possible explanation for the incorporation of PLO-DS into hybrid but not homogeneous 
oligomers may be related to the existence of different kinetic stages of oligomerization (20). In 
the  rate-limiting  initiation  reaction,  two or  more  monomers  react  with  one  another,  and the 
kinetic  handicaps  of  multiple  mutant  molecules  would  likely act  additively  at  this  stage.  In 
contrast, in the subsequent extension stage, growing oligomers reacts with further monomers one 
at  a  time.  In this  reaction,  kinetic  obstruction  would  only apply  to  one  of  the  partners  and 
therefore more readily overcome. Nevertheless, even in this situation, oligomerization of PLO-
DS is inhibited, resulting in the formation of incomplete, arc-shaped oligomers. Thus, wild type 
toxin promotes the oligomerization of the disulfide mutant, yet the latter inhibits oligomerization 
of the former; neither is entirely dominant. 
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Another interesting finding of this study is the pattern of hemolytic activity and of membrane 
insertion observed with hybrid oligomers. Mixing wild type PLO and PLO-DS likely produces a 
distribution  of  oligomers  that  differ  not  only  in  size  but  also  in  composition,  with  some 
oligomers containing a higher proportion of the disulfide mutant than others. Some oligomers 
containing no PLO-DS at all should also form; however, at a twofold excess of PLO-DS over  
wild type PLO, their number should be small. At this same ratio, approximately 50% of both 
membrane insertion and hemolytic  activity is still  preserved. Some of this remaining activity 
must therefore be associated with hybrid oligomers. This conclusion is supported by the fact that 
pores formed under these conditions are smaller on average than those formed by wild type toxin 
only.  In  contrast,  at  fourfold  or  greater  excess  of  PLO-DS,  electron  microscopy still  shows 
appreciable  formation  of  arc-shaped  oligomers,  but  hemolysis  is  sharply  reduced;  most 
oligomers therefore seem to be arrested at the pre-pore stage. 
These results signify that, with respect to membrane insertion as with oligomerization, neither 
the wild type toxin nor PLO-DS is clearly dominant over the other. Insertion of hybrids formed 
at  moderate  proportions  of  PLO-DS indicates  that  not  all  subunits  of  an  oligomer  need  to 
participate in its membrane insertion. On the other hand, its suppression by PLO-DS in greater 
proportion  indicates  that  membrane  insertion  requires  a  certain  critical  proportion  of  active 
subunits. Overall, these findings suggest that membrane insertion requires the cooperation of a 
number of adjacent subunits within the oligomer. 
In conclusion, our study provides additional insights into the mechanism of oligomerization and 
pore formation by CDCs. The initial conformational change that is associated with membrane 
binding and which sets the stage for oligomerization (ref) involves conformational flexibility 
between domains 2 and 3. The complementation of PLO-DS oligomerization by wild type PLO 
supports a two-step model of oligomerization that so far had been based on kinetic modeling 
only  (20). The fact  that  membrane insertion and pore formation can occur in oligomers  that 
contain some insertion-deficient subunits indicates that the process of insertion is only partially 
cooperative. 
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Figure Legends
Figure 1: Structure of PLO (homology model, based on the crystal structure of perfringolysin O 
(3)). The positions of the engineered disulfide bridge between residues 85 in domain 2 and 219 
in domain 3, as well as those of the additional cysteine mutations employed in this study are 
indicated.
Figure 2: Hemolytic activity of reduced and unreduced PLO-DS and of wild type PLO. Sheep 
RBC (0.5% in PBS) were incubated with the indicated amounts of PLO-WT or PLO-DS and 
incubated at 37 ºC for 30 minutes. The OD650 reflects the fraction of cells that remain intact after 
the incubation; hemolysis is apparent as a drop in the OD650.
Figure 3: Electron microscopy of wild type PLO and of PLO-DS, alone and in mixtures, on 
cholesterol crystals (negative staining with 2% uranyl acetate). The protein (0.125 mg/ml) and 
cholesterol crystals (0.5 mg/ml) were incubated for 30 minutes at room temperature. A: Wild 
type PLO, B: PLO-DS, C: Wild type PLO and PLO-DS 1:1, D:  Wild type PLO and PLO-DS 
1:10. 
Figure  4:  FRET experiments  on the  oligomerization  of  PLO-DS.  The active  single  cysteine 
mutant  N90C  and  the  triple  mutant  PLO-DS-K328C  were  labeled  with  fluorescein  (F)  or 
rhodamine  (R),  respectively.  The  labeled  proteins  were  incubated  with  membranes,  and the 
fluorescence emission was recorded with excitation at 465 nm. Solid lines represent spectra of 
equimolar  mixtures  of  fluorescein-  and  rhodamine-labeled  proteins;  dashed  lines  represent 
spectra of the fluorescein-labeled proteins only. A: Oligomerization of the active mutant N90C is 
evident by the suppression of fluorescein emission due to FRET to rhodamine. B: The triple 
mutant does not show significant FRET, indicating lack of oligomerization. C: FRET between 
N90C-F and rhodamine-labeled triple mutant indicates formation of hybrid oligomers. D: FRET 
between N90C-F and N90C-R in the presence of unlabeled PLO-DS or wild type PLO. The 
amount of unlabeled protein equaled the total of the labeled species.
Figure 5: Reduced size of hybrid oligomers, detected by gel filtration. The active mutant R219C 
was  labeled  with  fluorescein.  To  induce  oligomerization,  the  mutant  was  incubated  with 
membranes alone (hollow squares) or as a mixture with an equal amount of unlabeled PLO-DS. 
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The  membranes  were  solubilized  with  deoxycholate,  and  the  oligomers  were  applied  to  a 
Sephacryl  S400 column. The fluorescence of the eluate fractions was measured to detect the 
labeled protein. For comparison, a sample of labeled R219C not incubated with membranes is 
shown (hollow circles). 
Figure 6: Membrane insertion of domain 3 in hybrid oligomers.  Mutants K213C and A329C 
were  labeled  with  NBD,  and  the  fluorescence  emission  was  measured  in  the  absence  of 
membranes,  and after incubation with membranes either  alone or after  addition of unlabeled 
PLO-DS in twofold molar excess. The fluorescence increase after incubation with membranes 
reflects the extent of membrane insertion of the labeled, active mutants. 
Figure 7: Hemolytic activity of mixtures of wild type PLO in mixtures with PLO-DS. For each 
combination, the amounts of wild type and of PLO-DS are stated as multiples of the equivalents 
indicated on the x axis. The experimental procedure was as in Figure 2; drop of OD650 indicates 
hemolysis. 
Figure 8: Osmotic protection of red cells against mixtures of wild type PLO and PLO-DS by 
dextran 6 and dextran 40. Wild type PLO (2.5 μg/ml) alone (A) or with the same amount (B) or 
twice the amount (C) of PLO-DS was incubated in buffer, with or without dextran 6 or dextran 
40. The OD650 was followed over time; a drop in the  OD650 indicates hemolysis.
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